Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
Research output: Contribution to journal › Review › Research › peer-review
Standard
Pleiotropic Effects of Heparins : From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. / Korhan, Peyda; Yılmaz, Yeliz; Bağırsakçı, Ezgi; Güneş, Ayşim; Topel, Hande; Carr, Brian I; Atabey, Neşe.
In: Canadian Journal of Gastroenterology, Vol. 2018, 2018, p. 7568742.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pleiotropic Effects of Heparins
T2 - From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
AU - Korhan, Peyda
AU - Yılmaz, Yeliz
AU - Bağırsakçı, Ezgi
AU - Güneş, Ayşim
AU - Topel, Hande
AU - Carr, Brian I
AU - Atabey, Neşe
PY - 2018
Y1 - 2018
N2 - Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a common complication of HCC that is associated with a poor prognosis. Heparin derivatives are widely used in the management of venous thromboembolism (VTE). Among them low molecular weight heparin (LMWH) favorably influences the survival in patients with advanced cancer, including HCC. Due to their pleiotropic function, heparins affect tumorigenesis in many ways and may promote or hamper tumorigenic transformation depending on the cancer type and cancer stage along with their structural properties and concentration. Thus, their application as an antithrombotic along with the conventional therapy regime should be carefully planned to develop the best management strategies. In this review, we first will briefly review clinical applications of heparin derivatives in the management of cancer with a particular focus on HCC. We then summarize the state of knowledge whereby heparin can crosstalk with molecules playing a role in hepatocarcinogenesis. Lastly, we highlight new experimental and clinical research conducted with the aim of moving towards personalized therapy in cancer patients at risk of thromboembolism.
AB - Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a common complication of HCC that is associated with a poor prognosis. Heparin derivatives are widely used in the management of venous thromboembolism (VTE). Among them low molecular weight heparin (LMWH) favorably influences the survival in patients with advanced cancer, including HCC. Due to their pleiotropic function, heparins affect tumorigenesis in many ways and may promote or hamper tumorigenic transformation depending on the cancer type and cancer stage along with their structural properties and concentration. Thus, their application as an antithrombotic along with the conventional therapy regime should be carefully planned to develop the best management strategies. In this review, we first will briefly review clinical applications of heparin derivatives in the management of cancer with a particular focus on HCC. We then summarize the state of knowledge whereby heparin can crosstalk with molecules playing a role in hepatocarcinogenesis. Lastly, we highlight new experimental and clinical research conducted with the aim of moving towards personalized therapy in cancer patients at risk of thromboembolism.
KW - Anticoagulants/pharmacology
KW - Carcinogenesis/drug effects
KW - Carcinoma, Hepatocellular/complications
KW - Genetic Pleiotropy/drug effects
KW - Heparin/pharmacology
KW - Humans
KW - Liver Neoplasms/complications
KW - Venous Thromboembolism/drug therapy
U2 - 10.1155/2018/7568742
DO - 10.1155/2018/7568742
M3 - Review
C2 - 30425976
VL - 2018
SP - 7568742
JO - Canadian Journal of Gastroenterology
JF - Canadian Journal of Gastroenterology
SN - 2291-2789
ER -
ID: 389914113